Literature DB >> 12865406

The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.

Gregory B Lesinski1, Mirela Anghelina, Jason Zimmerer, Timothy Bakalakos, Brian Badgwell, Robin Parihar, Yan Hu, Brian Becknell, Gerard Abood, Abhik Ray Chaudhury, Cynthia Magro, Joan Durbin, William E Carson.   

Abstract

IFN-alpha activates the signal transducer and activator of transcription (STAT) family of proteins; however, it is unknown whether IFN-alpha exerts its antitumor actions primarily through a direct effect on malignant cells or by stimulating the immune system. To investigate the contribution of STAT1 signaling within the tumor, we generated a STAT1-deficient melanoma cell line, AGS-1. We reconstituted STAT1 into AGS-1 cells by retroviral gene transfer. The resulting cell line (AGS-1STAT1) showed normal regulation of IFN-alpha-stimulated genes (e.g., H2k, ISG-54) as compared with AGS-1 cells infected with the empty vector (AGS-1MSCV). However, mice challenged with the AGS-1, AGS-1STAT1, and AGS-1MSCV cell lines exhibited nearly identical survival in response to IFN-alpha treatment, indicating that restored STAT1 signaling within the tumor did not augment the antitumor activity of IFN-alpha. In contrast, STAT1-/- mice could not utilize exogenous IFN-alpha to inhibit the growth of STAT1+/+ melanoma cells in either an intraperitoneal tumor model or in the adjuvant setting. The survival of tumor-bearing STAT1-/- mice was identical regardless of treatment (IFN-alpha or PBS). Additional cell depletion studies demonstrated that NK cells mediated the antitumor effects of IFN-alpha. Thus, STAT1-mediated gene regulation within immune effectors was necessary for mediating the antitumor effects of IFN-alpha in this experimental system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865406      PMCID: PMC164283          DOI: 10.1172/JCI16603

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

1.  Interferon alfa-2a for melanoma metastases.

Authors:  John M Kirkwood; Joseph G Ibrahim; Vernon K Sondak; Marc S Ernstoff; Merrick Ross
Journal:  Lancet       Date:  2002-03-16       Impact factor: 79.321

2.  A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells.

Authors:  W E Carson; H Yu; J Dierksheide; K Pfeffer; P Bouchard; R Clark; J Durbin; A S Baldwin; J Peschon; P R Johnson; G Ku; H Baumann; M A Caligiuri
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

Review 3.  Signal transduction in the interferon system.

Authors:  S J Haque; B R Williams
Journal:  Semin Oncol       Date:  1998-02       Impact factor: 4.929

4.  Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides.

Authors:  K Suzuki; A Mori; K J Ishii; J Saito; D S Singer; D M Klinman; P R Krause; L D Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

5.  Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells.

Authors:  Suyun Huang; Corazon D Bucana; Melissa Van Arsdall; Isaiah J Fidler
Journal:  Oncogene       Date:  2002-04-11       Impact factor: 9.867

Review 6.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

7.  Time-dependent suppression of melanoma metastases and natural killer cell activation by interferon.

Authors:  M Ueda; Y Mishima; M Mojamdar; M Ichihashi; M Kita; T Kishida
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

8.  Structure, chromosome localization, and regulation of expression of the interferon-regulated mouse Ifi54/Ifi56 gene family.

Authors:  H A Bluyssen; R J Vlietstra; P W Faber; E M Smit; A Hagemeijer; J Trapman
Journal:  Genomics       Date:  1994-11-01       Impact factor: 5.736

9.  Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma.

Authors:  W E Carson
Journal:  Clin Cancer Res       Date:  1998-09       Impact factor: 12.531

10.  Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.

Authors:  R A Ezekowitz; J B Mulliken; J Folkman
Journal:  N Engl J Med       Date:  1992-05-28       Impact factor: 91.245

View more
  35 in total

1.  Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden.

Authors:  Peter J Klover; William J Muller; Gertraud W Robinson; Ruth M Pfeiffer; Daisuke Yamaji; Lothar Hennighausen
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

2.  Contrasting effects of IFNα on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter.

Authors:  Laura Pisapia; Giovanna Del Pozzo; Pasquale Barba; Alessandra Citro; Paul E Harris; Antonella Maffei
Journal:  Results Immunol       Date:  2012-09-27

Review 3.  Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.

Authors:  Mark A Perazella; Anushree C Shirali
Journal:  J Am Soc Nephrol       Date:  2018-06-29       Impact factor: 10.121

Review 4.  Interferons and their stimulated genes in the tumor microenvironment.

Authors:  Hyeonjoo Cheon; Ernest C Borden; George R Stark
Journal:  Semin Oncol       Date:  2014-02-14       Impact factor: 4.929

Review 5.  MicroRNAs and STAT interplay.

Authors:  Gary Kohanbash; Hideho Okada
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

6.  Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.

Authors:  Bethany L Mundy-Bosse; Gregory S Young; Todd Bauer; Elaine Binkley; Mark Bloomston; Matthew A Bill; Tanios Bekaii-Saab; William E Carson; Gregory B Lesinski
Journal:  Cancer Immunol Immunother       Date:  2011-05-21       Impact factor: 6.968

Review 7.  Altered macrophage differentiation and immune dysfunction in tumor development.

Authors:  Antonio Sica; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Authors:  Edit Porpaczy; Sabrina Tripolt; Andrea Hoelbl-Kovacic; Bettina Gisslinger; Zsuzsanna Bago-Horvath; Emilio Casanova-Hevia; Emmanuelle Clappier; Thomas Decker; Sabine Fajmann; Daniela A Fux; Georg Greiner; Sinan Gueltekin; Gerwin Heller; Harald Herkner; Gregor Hoermann; Jean-Jacques Kiladjian; Thomas Kolbe; Christoph Kornauth; Maria-Theresa Krauth; Robert Kralovics; Leonhard Muellauer; Mathias Mueller; Michaela Prchal-Murphy; Eva Maria Putz; Emmanuel Raffoux; Ana-Iris Schiefer; Klaus Schmetterer; Christine Schneckenleithner; Ingrid Simonitsch-Klupp; Cathrin Skrabs; Wolfgang R Sperr; Philipp Bernhard Staber; Birgit Strobl; Peter Valent; Ulrich Jaeger; Heinz Gisslinger; Veronika Sexl
Journal:  Blood       Date:  2018-06-14       Impact factor: 22.113

9.  Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells.

Authors:  Gregory B Lesinski; Jason M Zimmerer; Melanie Kreiner; John Trefry; Matthew A Bill; Gregory S Young; Brian Becknell; William E Carson
Journal:  BMC Cancer       Date:  2010-04-14       Impact factor: 4.430

10.  Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.

Authors:  Gregory B Lesinski; Kristen Benninger; Melanie Kreiner; Megan Quimper; Gregory Young; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2009-04-26       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.